Recently, the results of an early human phase clinical trial have shown that mRNA tech can be successfully applied to diseases other than COVID-19, such as skin cancer.

Moderna and Merck used an mRNA anti-cancer vaccine based on the same technology used to develop some COVID-19 vaccines, except that instead of using proteins from a virus to activate the immune system, they used some of the factors produced individually by the tumours owned by each of the patients.

Read more about this groundbreaking trial at MappingIgnorance.org